Secret. Designated as SECRET control officers are the Security Offi- cer and the Analysis, Records & Com- munications Manager, who have the re- sponsibility with respect to all infor- mation classified in this category:
Secret. The Parties shall keep secret all the information related to this Agreement and which are not in the public domain or belong to the other party, except the information contained in the PATENTS, which can be published by INRA, CNRS in scientific press. LMS, INRA TRANSFERT, INRA and CNRS shall only communicate the secret information to third parties, in whole or in part, with the prior written consent of the two other Parties. This obligation includes information related to LMS or INRA TRANSFERT sub-licences, their identity, their field of activity and the nature of the contract concluded with LMS or INRA TRANSFERT. This obligation shall remain in effect even after the expiry of the agreement and for as long as this information shall not be in the public domain. LMS and INRA TRANSFERT shall include this clause in their respective sublicense agreements.
Secret. Section 7.01. Each of the Parties undertakes to keep the Confidential Information secret for the duration of the Agreement and for a period of [**] after its termination or expiry. Each Party undertakes not to protect in the Field of Use, in any way whatsoever, all or part of the Confidential Information transmitted by the other Party, in particular by filing a patent application, and not to use them for any purpose other than those set out in Article 1, without the prior written consent of the latter. The Parties will ensure that their personnel and any person attached to their service in any capacity whatsoever are also be bound by this duty of confidentiality. The Parties hereby agree that any disclosure by the Company to a third party of any Confidential Information related to the invention protected by the Patent will be preceded by the signing of a confidentiality agreement with similar terms and conditions to those of this Article. The confidentiality agreements to which the Parties are bound pursuant to this Article shall not apply to information for which the receiving Party can prove: Certain confidential information contained in this document, marked by [**], has been omitted because SOPHiA GENETICS SA (SOPHiA) has determined that the information (i) is not material and (ii) is the type that SOPHiA customarily and actually treats as private or confidential.
Secret. 2.4.1 SECRET is used where compromise “could cause serious damage to national security, the Australian Government, nationally important economic and commercial interests or threaten life”. For example, compromise could:
Secret. Very sensitive information that justifies heightened protective measures to defend against determined and highly capable threats should be marked as “Secret”. For example, where compromise could seriously damage the investigation of very serious organised crime. The threat profile for “Secret” anticipates the need to defend against a higher level of capability than would be typical for the “Official” level. This includes sophisticated, well resourced and determined threats, such as highly capable serious organised crime groups.
Secret. Very sensitive information that justifies heightened protective measures to defend against determined and highly capable threat actors. For example, where compromise could seriously damage military capabilities, international relations or the investigation of serious organised crime.
Secret b. Of value;
Secret. 2.3.1 SECRET is very valuable, important and sensitive information with this classification used where compromise information “would be expected to cause serious damage to the national interest, organisations or individuals.” For example, compromise could:
Secret. 2.2. Upon the satisfaction of the Assignment Conditions, Amyris will promptly (and in any event no later than March 15, 2021) supply to DSM and DSM shall purchase up to [*]MT of Farnesene inventory at a price of $[*]/kg. for the sole purpose of selling such Farnesene to Givaudan to meet Givaudan’s [*] requirements. This supply of Farnesene inventory shall comply with all applicable requirements set forth in the Givaudan Farnesene Supply Agreement for DSM.
Secret. 9.2. Nothing in this Agreement shall prevent the disclosure of those parts of the Confidential Information which are required to be disclosed by (i) law or court order or (ii) pursuant to any listing agreement with, or the rules or regulations of, any national securities exchange on which any securities of such receiving Party or any Affiliate thereof is listed or traded; provided, however, that if the receiving Party is so required to disclose any such Confidential Information, it shall provide the disclosing Party prompt written notice of such requirement so that the disclosing Party may seek a protective order or other appropriate remedy to prevent or limit such disclosure. For the avoidance of doubt, prior to the assignment of the Givaudan Farnesene Supply Agreement, DSM shall not [*] unless approved in advance by Amyris.
